Home / Health / Daiichi Sankyo and General Proximity Forge Oncology Partnership to Advance Induced Proximity Medicines
Daiichi Sankyo and General Proximity Forge Oncology Partnership to Advance Induced Proximity Medicines
14 Nov
Summary
- General Proximity and Daiichi Sankyo collaborate on induced proximity medicines for cancer
- OmniTAC discovery platform to identify new effector-target pairs for first-in-class therapies
- Daiichi Sankyo is a leader in oncology research and development
On November 14, 2025, General Proximity announced a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to oncology programmes. The collaboration will focus on discovering and advancing induced proximity medicines for cancer treatment.
These innovative medicines facilitate accurate and selective alteration of disease-causing proteins, opening up therapeutic possibilities for targets that have been difficult to address using traditional methods. General Proximity's OmniTAC platform enables unbiased screening of effector proteins that can modulate disease-relevant targets, offering a distinct pathway for drug discovery.
Daiichi Sankyo, a leader in oncology research and development, entered the collaboration through its Research Institute located in Boston, Massachusetts. General Proximity founder and CEO Armand Cognetta expressed excitement to work with such a strong collaborator, stating that the agreement represents an important validation of their novel induced proximity approach and the potential of the OmniTAC platform to deliver innovative solutions for patients.
